Artiva Biotherapeutics, Inc.
ARTV
$11.78
$0.564.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 0.00 | 0.00 | 0.00 |
| SG&A Expenses | 20.27M | 20.27M | 20.28M | 19.83M | 18.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.07M | 89.81M | 86.15M | 81.58M | 74.96M |
| Operating Income | -92.07M | -89.81M | -86.15M | -81.58M | -74.96M |
| Income Before Tax | -87.07M | -83.87M | -79.19M | -75.13M | -71.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.07 | -83.87 | -79.19 | -75.13 | -71.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.07M | -83.87M | -79.19M | -75.13M | -71.72M |
| EBIT | -92.07M | -89.81M | -86.15M | -81.58M | -74.96M |
| EBITDA | -89.43M | -87.21M | -83.60M | -79.07M | -72.49M |
| EPS Basic | -3.55 | -3.43 | -3.25 | -3.29 | -24.41 |
| Normalized Basic EPS | -2.27 | -2.19 | -2.09 | -2.12 | -15.32 |
| EPS Diluted | -3.55 | -3.43 | -3.25 | -3.29 | -24.41 |
| Normalized Diluted EPS | -2.27 | -2.19 | -2.09 | -2.12 | -15.32 |
| Average Basic Shares Outstanding | 98.11M | 97.77M | 97.59M | 92.00M | 68.44M |
| Average Diluted Shares Outstanding | 98.11M | 97.77M | 97.59M | 92.00M | 68.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |